Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

Dyne Therapeutics is utilizing their innovative FORCE platform to develop targeted therapeutics for genetically driven neuromuscular diseases, which has shown positive results in clinical data and has the potential to transform the treatment landscape for these diseases. The company's diverse portfolio of treatments in various stages of development, as well as its well-documented and transparent governance, make it an attractive investment opportunity. However, there are inherent risks in the biotech industry and Dyne Therapeutics is not immune to uncertainties in clinical trial execution and regulatory approvals. Nevertheless, the company's pioneering approach gives it a competitive advantage and we believe there is potential for significant success and value creation in the long-term.

Bears say

Dyne Therapeutics is focused on developing life-transforming therapeutics for neuromuscular diseases, but their clinical trial for DYNE-101 recently missed the primary endpoint, causing concern about the effectiveness of their delivery platform. Additionally, their main competitor, Sarepta, has already generated significant revenue for DMD treatment, making it difficult for Dyne to break into the market. This, combined with potential clinical risks, such as regulatory uncertainties and failure to demonstrate efficacy, lead to a negative outlook for the company's future performance.

Dyne Therapeutics (DYN) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 10 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.